Exvastat announces collaborator start of Phase II trial of imatinib in Severe COVID-19

Exvastat’s collaborator, Vrije Universiteit Amsterdam has started a Phase II clinical study to determine the effect of oral imatinib in the treatment of Severe COVID-19 disease. Designed as a randomized, double-blind, placebo controlled, clinical trial in 386 patients, the study will investigate the progression of patients hospitalised in the Netherlands with severe COVID-19 and their transition into the intensive care unit.

As an oral medication, the treatment will not be tailored for administration to ventilated, sedated patients in the ICU, and for that purpose, an ancillary programme for the administration of an intravenous formulation is being undertaken by Exvastat.